Even in the modern era of targeted therapies, allogeneic hematopoietic stem cell transplantation (allo-HCT) can offer a chance of extended survival in B cell non-Hodgkin lymphoma (B-NHL) patients who relapse after or are deemed ineligible for autologous transplantation. A better understanding of the factors influencing the graft-versus-lymphoma (GVL) response would be useful in identifying B-NHL patients who may benefit from allo-HCT. Based on prior single-center reports, we hypothesized that certain HLA alleles, or haplotypes, may be associated with superior GVL compared with others after allo-HCT. To test this possibility we retrospectively evaluated whether the presence of HLA-A2, HLA-C1C1, HLA-DRB1*01:01, or HLA-DRB1*13 alleles or the presence of HLA-A1+, HLA-A2-, and HLA-B44- haplotypes is associated with outcomes in a cohort of 1314 HLA-8/8 matched sibling or unrelated donor HCT for relapsed/refractory B-NHL. We observed no significant association between any HLA allele or haplotype and overall survival or any of the secondary endpoints. In conclusion, this study represents the largest reported series of allo-HCT outcomes of B-NHL patients based on HLA type. Identification of other variables will be required to delineate the immunologic impact of donor–host interactions on outcomes of allo-HCT for B-NHL.
Bibliographical noteFunding Information:
Financial disclosure : The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases ; a Grant/Cooperative Agreement 4U10HL069294 from the NHLBI and NCI; contract HHSH250201200016C with Health Resources and Services Administration ; 2 grants ( N00014-17-1-2388 and N00014-16-1-2020) from the Office of Naval Research ; and grants from * Actinium Pharmaceuticals ; * Amgen, Inc. ; * Amneal Biosciences ; * Angiocrine Bioscience, Inc. ; Anonymous donation to the Medical College of Wisconsin ; Astellas Pharma US ; Atara Biotherapeutics, Inc. ; Be The Match Foundation ; * bluebird bio, Inc. ; * Bristol Myers Squibb Oncology ; * Celgene Corporation ; Cerus Corporation ; * Chimerix, Inc. ; Fred Hutchinson Cancer Research Center ; Gamida Cell Ltd. ; Gilead Sciences, Inc. ; HistoGenetics, Inc. ; Immucor ; * Incyte Corporation ; Janssen Scientific Affairs, LLC ; * Jazz Pharmaceuticals ; Juno Therapeutics; Karyopharm Therapeutics, Inc. ; Kite Pharma, Inc. ; Medac, GmbH ; MedImmune ; Medical College of Wisconsin ; * Merck & Co., Inc. ; * Mesoblast ; MesoScale Diagnostics, Inc. ; Millennium, the Takeda Oncology Co. ; * Miltenyi Biotec, Inc. ; National Marrow Donor Program; * Neovii Biotech NA, Inc. ; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co, Ltd. – Japan ; PCORI ; * Pfizer, Inc ; * Pharmacyclics, LLC ; PIRCHE AG ; * Sanofi Genzyme ; * Seattle Genetics ; Shire ; Spectrum Pharmaceuticals, Inc. ; St. Baldrick's Foundation ; * Sunesis Pharmaceuticals, Inc. ; Swedish Orphan Biovitrum, Inc. ; Takeda Oncology ; Telomere Diagnostics, Inc. ; and University of Minnesota . Asterisk indicates corporate members The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration, or any other agency of the US Government.
- Allogeneic transplant
- B cell